Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026)

Protalix BioTherapeutics has reported Finished Goods for 10 years, with the latest figure at $15.4 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 119.15% year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (up 119.15% YoY), and the FY2025 full-year result was $10.4 million, up 90.38% from the prior year.
• Finished Goods for Q1 2026 stood at $15.4 million, up from $10.4 million in the prior quarter.
• The five-year high for Finished Goods was $15.4 million in Q1 2026, with the low at $706000.0 in Q3 2024.
• Average Finished Goods over 5 years is $9.0 million, with a median of $9.2 million recorded in 2024.
• Year-over-year, Finished Goods plunged 91.46% in 2024 and surged 1446.32% in 2025.
• Tracing PLX's Finished Goods over 5 years: stood at $10.6 million in 2022, then slumped by 45.24% to $5.8 million in 2023, then dropped by 6.28% to $5.4 million in 2024, then jumped by 90.38% to $10.4 million in 2025, then jumped by 48.29% to $15.4 million in 2026.
• The last three Finished Goods figures came in at $15.4 million (Q1 2026), $10.4 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.

Peer Comparison